scispace - formally typeset
G

Gianluca Testa

Researcher at University of Molise

Publications -  85
Citations -  4952

Gianluca Testa is an academic researcher from University of Molise. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 27, co-authored 78 publications receiving 3447 citations. Previous affiliations of Gianluca Testa include University of Naples Federico II & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Oxidative stress, aging, and diseases.

TL;DR: Given the important role of oxidative stress in the pathogenesis of many clinical conditions and aging, antioxidant therapy could positively affect the natural history of several diseases, but further investigation is needed to evaluate the real efficacy of these therapeutic interventions.
Journal ArticleDOI

Frailty predicts long‐term mortality in elderly subjects with chronic heart failure

TL;DR: Examination of the predictive role of frailty on long‐term mortality in elderly subjects with CHF found it to be a significant predictor of long-term mortality.
Journal ArticleDOI

Sarcopenia: assessment of disease burden and strategies to improve outcomes.

TL;DR: Because sarcopenia is associated with important adverse health outcomes, such as frailty, hospitalization, and mortality, several therapeutic strategies have been identified that involve exercise training, nutritional supplementation, hormonal therapies, and novel strategies and are still under investigation.
Journal ArticleDOI

Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis

TL;DR: A continuum among hypertension, coronary artery disease, atrial fibrillation and chronic heart failure with to the development of cognitive impairment and progression to dementia has been hypothesized.
Journal ArticleDOI

Biomarkers in sarcopenia: A multifactorial approach

TL;DR: In order to characterize pathophysiological mechanisms and to make a correct assessment of elderly patient with sarcopenia, a panel of biomarkers of all pathways involved should be assessed.